Catalog No.
PHC07601
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human MYCN (Asp48-Arg138).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
BHLHE37, bHLHe37, Class E basic helix-loop-helix protein 37, N-myc proto-oncogene protein, MYCN, NMYC
Purification
Purified by antigen affinity column.
Accession
P04198
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Inhibition of Purine Metabolism Promotes the Differentiation of Neuroblastoma Driven by MYCN., PMID:40353332
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission., PMID:40067131
Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status., PMID:39407175
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways., PMID:39380995
The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma., PMID:39307412
Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma., PMID:39255035
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate., PMID:39128771
Multi-omics and pharmacological characterization of patient-derived glioma cell lines., PMID:39112531
Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field., PMID:38880415
Development of red blood cell-derived extracellular particles as a biocompatible nanocarrier of microRNA-204 (REP-204) to harness anti-neuroblastoma effect., PMID:38852882
Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy., PMID:38731089
Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells., PMID:38730731
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy., PMID:38730688
A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations., PMID:38702304
Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features., PMID:38229432
Partial Response to Naxitamab for Brain Metastasis in Neuroblastoma., PMID:38189408
PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma., PMID:38125723
Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy., PMID:37602920
Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma., PMID:37408891
Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy., PMID:37247922
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report., PMID:37174002
Impaired Antitumor Immune Response in MYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment., PMID:36923280
Anti-GD2 immunoliposomes loaded with oxamate for neuroblastoma., PMID:36788290
Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in MYCN Non-Amplified Neuroblastoma., PMID:36775958
Clinical significance of MYC family protein expression in surgically resected high-grade neuroendocrine carcinoma of the lung., PMID:36694106
Development of minimally invasive cancer immunotherapy using anti-disialoganglioside GD2 antibody-producing mesenchymal stem cells for a neuroblastoma mouse model., PMID:36484857
Expression of programmed cell death-1 on neuroblastoma cells in TH-MYCN transgenic mice., PMID:36441248
Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma., PMID:36185250
MYCN protein stability is a better prognostic indicator in neuroblastoma., PMID:35820898
TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy., PMID:35646475
Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries., PMID:35084087
Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma., PMID:34655293
Enzymatic Spermine Metabolites Induce Apoptosis Associated with Increase of p53, caspase-3 and miR-34a in Both Neuroblastoma Cells, SJNKP and the N-Myc-Amplified Form IMR5., PMID:34440719
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope., PMID:34337560
Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies., PMID:34298713
NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers., PMID:34277416
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study., PMID:34152804
Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission., PMID:34022112
Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?, PMID:33932141
Thiotepa-melphalan myeloablative therapy for high-risk neuroblastoma., PMID:33788375
Targeting netrin-3 in small cell lung cancer and neuroblastoma., PMID:33719214
Alternative approaches to target Myc for cancer treatment., PMID:33692331
The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL)., PMID:33271265
Exosomes: Novel Players of Therapy Resistance in Neuroblastoma., PMID:33119866
Immune characterization of pre-clinical murine models of neuroblastoma., PMID:33028899
Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor., PMID:32982239
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma., PMID:32653773
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes., PMID:32584970
Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience., PMID:32543116
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies., PMID:32503469
For research use only. Not for human or drug use.
